New Leadership in Neuroscience
NewcelX Ltd. (NASDAQ: NCEL), a forward-thinking biotechnology company, is thrilled to enhance its Scientific Advisory Board with the addition of Professor Tamir Ben-Hur, a distinguished neurologist recognized worldwide for his contributions in neuroimmunology and stem cell-based treatments.
Background of Professor Ben-Hur
Prof. Ben-Hur serves as a Professor of Neurology at Hadassah University Medical Center as well as the Hebrew University of Jerusalem. His extensive expertise in regenerative medicine positions him as an invaluable asset to NewcelX's mission of advancing therapies for neurodegenerative diseases.
Prof. Ben-Hur's Vision
Expressing his enthusiasm, Prof. Ben-Hur stated, "Joining NewcelX is an incredible opportunity to contribute to a biotechnology company that is committed to pioneering regenerative therapies. I look forward to leveraging our collective strengths in neuroscience to foster significant advancements for patients globally." His commitment highlights the potential impact of innovative treatments in areas such as ALS and diabetes.
Strategic Insights from Company Executives
Prof. Michel Revel, Chief Scientific Officer at NewcelX, emphasized, "The addition of Prof. Ben-Hur to our team enriches our clinical perspective. His experience aligns perfectly with our goal of addressing the underlying causes of neurodegenerative conditions through groundbreaking cell therapies." This collaboration is set to drive NewcelX's research and development initiatives forward.
The Future of NewcelX
Ronen Twito, Executive Chairman and CEO of NewcelX, declared, "We are privileged to welcome Prof. Ben-Hur to our scientific community. His decision to join signifies his confidence in our vision and the scientific work we are undertaking to transform patient care in neurology and beyond." This partnership reinforces the integration of advanced stem cell technologies with expertise in cutting-edge neuroscience.
About NewcelX Ltd.
NewcelX Ltd. (NASDAQ: NCEL) is firmly focused on developing innovative cell-based and small-molecule therapies aimed at treating various neurodegenerative and metabolic diseases. Their integrated approach utilizes sophisticated stem cell techniques and neuroscientific knowledge to address critical health conditions, including ALS and Type 1 Diabetes. With its headquarters in Zurich, Switzerland, and R&D operations in Israel, NewcelX is positioned for substantial growth and impact in the healthcare sector.
Social Media Connections
Stay connected with NewcelX through their social media pages for updates and insights into their ongoing research efforts: LinkedIn, Facebook, and X. These platforms facilitate communication about new developments and share their journey in advancing biotechnology.
Frequently Asked Questions
What role will Professor Ben-Hur play at NewcelX?
Professor Ben-Hur will contribute his expertise in neuroimmunology as a member of the Scientific Advisory Board, guiding the company in advancing their therapeutic developments.
What areas of research is NewcelX focused on?
NewcelX concentrates on neurodegenerative and metabolic diseases, aiming to develop innovative cell-based therapies targeting conditions such as ALS and diabetes.
How does NewcelX plan to achieve its therapeutic goals?
The company combines advanced stem cell technologies with neuroscience expertise to develop impactful and scalable treatments for patients worldwide.
Where is NewcelX headquartered?
NewcelX is headquartered in Zurich, Switzerland, with additional research and development operations located in Ness Ziona, Israel.
How can I contact NewcelX for more information?
For investor inquiries, please reach out to Sarah Bazak via email at InvestorRelations@newcelx.com. You can also visit their official website for additional information.
